As the final quarter of 2025 unfolds, the commercial pharma landscape is being reshaped by a wave of high-impact catalysts.
From pivotal PDUFA decisions and late-stage data readouts to strategic acquisitions and deal activity, this report delivers a comprehensive view of the forces driving market momentum.
Inside the report:
- 29 drug catalysts expected to move the market in Q4
- Key FDA approval decisions across oncology, rare disease, and respiratory
- Data readouts from Phase II and III trials with commercial implications
- Strategic M&A activity including BioNTech, Sanofi, Novartis, and more
- Commercial tracking of emerging therapies and pipeline shifts
Download Now
